Billionaire Profile
Dennis Gillings
Global Rank
#1847

Image: Richter Frank-Jurgen | CC BY-SA 2.0 | via Wikimedia Commons

Dennis Gillings

CEO, Clinical trials
UNITED KINGDOM
Real-Time Net Worth
$2.233B
Estimated based on Clinical trials stock value as of March 6, 2026
-0.22% (24h)
Age
81
Source
Clinical trials
Industry
Healthcare
Citizenship
UNITED KINGDOM

Biography

Sir Dennis Gillings is a British-American businessman and philanthropist, best known as the founder of IQVIA (formerly Quintiles). Born in 1944, Gillings's career spans from academia, as a biostatistics professor, to becoming a leading figure in the healthcare industry. His wealth source stems from the clinical trials and healthcare data analytics sectors, with a current net worth of $2.1 billion. Gillings is recognized for his entrepreneurial spirit, having taken Quintiles public and then private again. He is also celebrated for his significant philanthropic contributions to medical research, education, and global health initiatives. As of 2024, Gillings continues to be actively involved in philanthropic and industry leadership roles, leaving a lasting impact on the global healthcare landscape.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Dennis Barry Gillings was born on April 25, 1944, in London, England. He is the son of a fishmonger and attended Coopers' Company School. Gillings earned a BSc in mathematics in 1966, a diploma in mathematical statistics from Cambridge University, and a PhD in mathematics in 1972, all from the University of Exeter. His academic background formed a strong foundation for his future business endeavors.

Rise to Success

Gillings began his professional career as a professor of biostatistics at the University of North Carolina at Chapel Hill. In 1974, he started providing statistical consulting and data management services to pharmaceutical clients. In 1982, he founded Quintiles, a contract research organization (CRO) focused on providing outsourced services to the pharmaceutical, biotechnology, and healthcare industries. Quintiles quickly expanded and, under Gillings' leadership, became one of the largest companies of its kind globally. He took Quintiles public in 1994 and then led a leveraged buyout to take the company private again in 2003. Quintiles then went public for a second time in 2013. In 2016, Quintiles rebranded as IQVIA after merging with IMS Health.

Key Business Strategies

Gillings's key business strategy involved leveraging data and technology to revolutionize the healthcare industry. His vision was to provide data-driven insights that would help pharmaceutical companies, healthcare providers, and researchers make better-informed decisions. Quintiles and later IQVIA expanded through strategic acquisitions and investments, becoming an essential partner for global healthcare organizations. The company's success is attributed to Gillings's drive for excellence and his ability to stay ahead of industry trends.

Philanthropy

Throughout his career, Gillings has been a committed philanthropist, with his philanthropic work closely tied to his passion for improving healthcare worldwide. He has donated millions of dollars to causes related to medical research, public health, and education. Notably, he has supported the University of Exeter, endowing the Dennis Gillings Professor of Health Management at the University of Cambridge, and the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, which bears his name due to a $50 million donation.

Career Milestones

1971

Professor of Biostatistics

Began teaching biostatistics at the University of North Carolina at Chapel Hill.

1982

Founded Quintiles

Founded Quintiles, a contract research organization.

1994

Quintiles IPO

Took Quintiles public through an initial public offering.

2003

Quintiles Privatization

Led a leveraged buyout to take Quintiles private.

2013

Second Quintiles IPO

Quintiles went public for a second time.

2015

Retired as Executive Chairman of Quintiles

Retired as Executive Chairman, remaining a director.

2016

IQVIA Rebranding

Quintiles rebranded as IQVIA after merging with IMS Health.

2020

Knighted

Knighted in the 2020 New Year Honours for services to the advancement of dementia and life sciences research.

Philanthropy & Social Impact

Education

Gillings School of Global Public Health

$50M

Donated to the University of North Carolina to name the School of Public Health.

Public Health

Dennis and Mireille Gillings Global Public Health Fellowships

Unknown

Supports fellowships for scientific and business leaders in global public health through the Pasteur Foundation US and the Institut Pasteur.

Cancer Research

EORTC Cancer Research Fund

€1M

Pledged to the European Organisation for Research and Treatment of Cancer (EORTC) Research Fund.

Medical Research

Academy of Medical Sciences

£1.35M

Donated to a leadership program for biomedical and health scientists through the Academy of Medical Sciences

Business Philosophy & Leadership

Notable Quotes

"We need new leaders in the health research sector that can seize opportunities and overcome hurdles to work across sectors."

"The vision that Dennis displayed in the early years of Quintiles led to a revolution in the way drug development is conducted."

Leadership Principles

Data-Driven Insights

Emphasizes the use of data and technology to make informed decisions in healthcare.

Innovation

Continuously seeks to leverage new technology and data to improve the efficiency of clinical trials and overall healthcare.

Partnership

Building strong relationships with biopharmaceutical companies and healthcare providers to become a true partner rather than a task manager